Ramanathan RK, et al. - Researchers conducted this phase II study to assess the efficacy of therapy selected by immunohistochemistry (IHC) in metastatic pancreatic cancer patients following progression after one or more therapies. Findings revealed identification of at least two targets for therapy in all patients with IHC assays. Thereby suggesting prescription of a non-cross resistant regimen for therapy with evidence of some benefit in these patients. An IHC based treatment strategy seemed feasible and required validation in larger studies.